BRAF Inhibitor and Checkpoint Inhibitor Combination for Melanoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic melanoma, particularly those involving B-RAF inhibitors, often lead to disease recurrence and have limited efficacy in extending progression-free survival and overall survival, with side effects and resistance issues, necessitating the exploration of combination therapies that enhance response rates and duration.
Innovation Solution
Combining a B-RAF inhibitor with an immune checkpoint inhibitor, either alone or in conjunction with a MEK inhibitor, to create a treatment regimen that targets B-RAF V600-mutant melanoma, with specific dosing schedules and drug combinations such as vemurafenib and atezolizumab or vemurafenib and cobimetinib, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If B-RAF inhibitors are used to treat metastatic melanoma, then response rates improve, but disease recurrence occurs and progression-free survival is limited
Solution Approach 1:
The patent combines B-RAF inhibitors with immune checkpoint inhibitors (such as anti-CTLA-4 or anti-PD-1 antibodies) in a unified treatment regimen. This combination therapy merges two different mechanisms of action: B-RAF inhibition to directly target mutant melanoma cells and immune checkpoint inhibition to enhance T-cell-mediated anti-tumor immunity, thereby improving both response rate and durability of response while reducing disease recurrence
Solution Approach 2:
The treatment protocol uses a composite therapeutic approach by integrating multiple drugs with different mechanisms of action. The B-RAF inhibitor (e.g., vemurafenib or dabrafenib) works alongside immune checkpoint inhibitors (e.g., ipilimumab, nivolumab, or pembrolizumab) to create a synergistic effect that addresses both the immediate need for tumor cell death and the long-term need for sustained immune surveillance to prevent recurrence
2Device complexity
If B-RAF inhibitors are used alone, then treatment is simple, but overall survival extension is limited
Solution Approach 1:
The patent merges B-RAF inhibition with immune checkpoint inhibition in a coordinated treatment regimen. This combination is administered in a structured manner: B-RAF inhibitor is given continuously or in cycles, while immune checkpoint inhibitor is administered at specific intervals (e.g., every 3 weeks or every 6 weeks). This merged approach extends overall survival by engaging both direct anti-tumor effects and sustained immune-mediated control
Solution Approach 2:
The treatment protocol incorporates preliminary action by administering B-RAF inhibitor first to rapidly reduce tumor burden and induce tumor antigen release, which primes the immune system. This is followed by or combined with immune checkpoint inhibitor to sustain and amplify the immune response, thereby extending overall survival through a sequenced therapeutic strategy
3Productivity
If B-RAF inhibitors are used, then initial response is achieved, but resistance develops over time
Solution Approach 1:
The patent combines B-RAF inhibitors with immune checkpoint inhibitors to create a dual-mechanism therapy that prevents resistance. The B-RAF inhibitor provides initial rapid response by directly inhibiting mutant BRAF signaling, while the immune checkpoint inhibitor simultaneously engages the immune system to provide sustained anti-tumor activity through multiple mechanisms, making it harder for the tumor to develop resistance
Solution Approach 2:
The treatment strategy employs parameter changes by dynamically adjusting the dosing schedules and combinations of B-RAF inhibitor and immune checkpoint inhibitor based on patient response and tolerability. This may include modifying the frequency of immune checkpoint inhibitor administration or adjusting B-RAF inhibitor dosage to maintain optimal therapeutic levels while minimizing resistance development
Data Source
AI summary
Provided herein are therapies including dosage regimens for the treatment of cancer using B-RAF and an immune checkpoint inhibitor in combination with and/or without a MEK inhibitor.